Physician profile
Robert Purvis
NPI 1154373827
$15,361.01
in general payments reported to CMS, 2019-2025
37 companies · $3,760 in 2025
The $3,760 reported for 2025 was more than what 87% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,755 · 2020: $598 · 2021: $1,806 · 2022: $2,018 · 2023: $2,031 · 2024: $2,393 · 2025: $3,760.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,844 · Education: $340.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,844.35 |
| Education | $339.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,970.07 | 2019-2025 | |
| Sun Pharmaceutical Industries INC. | $1,718.69 | 2019-2025 | Ilumya, Blu-U, Odomzo |
| Regeneron Healthcare Solutions, INC. | $1,377.48 | 2019-2025 | Dupixent, Libtayo |
| Janssen Biotech, INC. | $1,318.68 | 2019-2025 | Tremfya, Stelara, Simponi Aria |
| Incyte Corporation | $1,096.94 | 2021-2025 | Opzelura, Opzelura |
| Pfizer INC. | $971.77 | 2019-2025 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $769.02 | 2019-2024 | Arazlo, Duobrii, Cabtreo |
| Janssen Scientific Affairs, LLC | $643.45 | 2023-2025 | Tremfya |
| Arcutis Biotherapeutics, INC. | $586.60 | 2023-2025 | Zoryve |
| Genzyme Corporation | $524.07 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $458.40 | 2019-2025 | |
| Lilly USA, LLC | $444.46 | 2019-2025 | Ebglyss, Taltz, Olumiant |
| Leo Pharma INC. | $403.31 | 2021-2025 | Adbry, Anzupgo |
| Sanofi-Aventis U.S. LLC | $384.72 | 2019-2021 | |
| Amgen INC. | $322.33 | 2020-2022 |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $315.37 | 2019 | |
| Almirall LLC | $226.01 | 2019-2025 | Klisyri, Seysara |
| E.R. Squibb & Sons, L.L.C. | $213.47 | 2022-2025 | Sotyktu |
| Organogenesis INC. | $185.90 | 2023-2025 | Puraply, Novachor |
| Ucb, INC. | $181.25 | 2019-2025 | Bimzelx |
| Boehringer Ingelheim Pharmaceuticals, INC. | $166.55 | 2023-2025 | Spevigo |
| Galderma Laboratories, L.P. | $157.01 | 2024-2025 | Nemluvio |
| Genentech USA, INC. | $121.12 | 2019-2023 | Erivedge |
| Dermira, INC. | $115.74 | 2019 | |
| Biofrontera INC. | $109.69 | 2022-2025 | Rhodoled Xl, Ameluz, Xepi |
| Dermavant Sciences, INC. | $103.29 | 2023-2024 | Vtama |
| Kerecis Limited | $99.23 | 2024-2025 | Kerecis Omega3 Marigen, Kerecis Surgiclose, Kerecis Omega3 Surgiclose |
| Caris Mpi, INC. | $80.00 | 2025 | Mi Cancer Seek |
| Verrica Pharmaceuticals INC. | $79.62 | 2024 | Ycanth |
| Journey Medical Corporation | $69.96 | 2021-2022 | |
| Helsinn Therapeutics (U.S.), INC. | $36.96 | 2019-2022 | |
| Paratek Pharmaceuticals, INC. | $24.18 | 2021 | |
| Biowound Solutions, INC. | $23.41 | 2025 | Bio-Connekt |
| Strata Skin Sciences, INC. | $21.02 | 2024 | Xtrac |
| Mayne Pharma Commercial LLC | $17.56 | 2019 | |
| Myriad Genetic Laboratories, INC. | $11.85 | 2021 | |
| Misonix INC | $11.83 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Purvis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.